New Search

Export article

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial

Zhan Wang, Bao-Dong Qin, Chen-Yang Ye, Miao-Miao Wang, Ling-Yan Yuan, Wei-Ping Dai, Li Sun, Ke Liu, Wen-Xing Qin, Xiao-Dong Jiao,
Show More
Published: 21 January 2022
 by  Elsevier BV
 in European Journal of Cancer
European Journal of Cancer , Volume 163, pp 152-162; https://doi.org/10.1016/j.ejca.2021.12.028

Publisher Website
Full-Text
Google Scholar
Show/hide abstract
The publisher has not yet granted permission to display this abstract.
Keywords: Colorectal cancer / BRAF V600E mutation / FOLFIRI / Cetuximab / Vemurafenib / ERK / Extracellular signal-regulated kinase / MEK / Mitogen-activated protein kinase / mCRC / Metastatic colorectal cancer / BRAF / v-raf murine sarcoma viral oncogene homolog B1 / mOS / Median overall survival / mPFS / Median Progression-free survival / AEs / Adverse events

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "European Journal of Cancer" .
References (26)
    For questions or feedback, please reach us at support___at___scilit.net
    © 2022 MDPI (Basel, Switzerland) unless otherwise stated
    Terms and Conditions
    Back to Top Top